Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with knee osteoarthritis. A 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled, dose-ranging study. ROCCELLA Study

Trial Profile

Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with knee osteoarthritis. A 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled, dose-ranging study. ROCCELLA Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs GLPG 1972 (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms ROCCELLA
  • Sponsors Galapagos NV
  • Most Recent Events

    • 24 Sep 2018 According to a Galapagos NV media release, first patient has been dosed and received 9 million euros milestone payment from its collaboration partner Servier for this achievement.
    • 23 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 13 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top